Videos

Lori Wirth, MD, discusses her experience with NTRK-targeted therapies for patients with thyroid cancer.

Ravi Salgia, MD, PhD, discusses the ways in which oncologists can watch out for non-small cell lung cancer that transforms to small-cell lung cancer.

Description: Before closing out his discussion on polycythemia vera management, Prithviraj Bose, MD, shares excitement for emerging therapeutics in this setting.

Expert perspectives on long-term management of patients with polycythemia vera, with regard for the risk of developing secondary MF or AML.

In discussing the role of ruxolitinib in HU-resistant or intolerant PV, expert Prithviraj Bose, MD, highlights data from the RESPONSE and RESPONSE-2 clinical trials.

Considerations for therapy when patients with polycythemia vera experience hydroxyurea resistance or intolerance.

A comprehensive review of the treatment armamentarium for polycythemia vera, as well as strategies to monitor patients on therapy in this setting.

Expert Prithviraj Bose, MD, reviews standard practices in diagnosing and risk stratifying uncontrolled polycythemia vera in the context of a patient case.

Andreas Saltos, MD, discusses a phase 1 trial of binimetinib and erlotinib for patients with non–small cell lung cancer and EGFR or KRAS mutations.

In this companion article, Dr. Jyoti Malhotra discusses her clinical experience using trilaciclib for the management of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer.

Steven M. Albelda, MD, discusses the limited successes of CAR T cells in solid tumors.

Shawn Dason, MD, a urologic oncologist at The Ohio State University Comprehensive Cancer Center, discusses the decline of prostate cancer screening in recent years and how it has impacted care of patients with prostate cancer overall.

David Barrington, MD, discusses adjuvant treatments that are currently available for patients with stage 1B, grade 3 endometrial cancer.

Nazli Dizman, MD, discusses what community oncologists should keep in mind about gut microbiome when treating their patients.

John L. Marshall, MD, discusses of the adverse event profile of fam-trastuzumab deruxtecan-nxki in patients with locally advanced or metastatic HER2-positive gastric cancer.

Mazyar Shadman, MD, MPH, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma and chronic lymphocytic leukemia.

Before closing out his discussion on newly diagnosed multiple myeloma, Ajay K. Nooka, MD, MPH, FACP, emphasizes the continued role of transplantation in this setting.

Ajay K. Nooka, MD, MPH, FACP, shares insight on strategies to optimally deliver maintenance therapy and manage toxicities in patients with multiple myeloma.

Considerations for assessing treatment response and electing to continue therapy in patients with newly diagnosed multiple myeloma.

Insight on the role of isatuximab and VRd in patients with newly diagnosed multiple myeloma following data from the GMMG-HD7 study.

Shifting his focus to the MASTER study in newly diagnosed multiple myeloma, Ajay K. Nooka, MD, MPH, FACP, highlights the role of daratumumab with KRd.

Expert perspectives on the use of daratumumab with RVd in patients with newly diagnosed multiple myeloma in the context of updates from the GRIFFIN study.

Expert hematologist-oncologist Ajay K. Nooka, MD, MPH, FACP, shares his perspective on the management of a woman newly diagnosed with multiple myeloma.

Tanios S. Bekaii-Saab, MD, FACP, discusses the differences between adagrasib and other KRAS inhibitors.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Drs. Shaji Kumar and Jonathan Kaufman discuss how BCL-2 inhibitors fit into the different treatment options for multiple myeloma.

Sophia Kamran, MD, discusses the research supporting the use of trimodality therapy with immunotherapy for patients with urothelial cancer.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. An explanation of the focus on BCL-2 inhibitors versus the development of MCL-1 inhibitors for multiple myeloma treatment.

Andrew Wei, MBBS, PhD, discusses outcomes related to long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.

Hagop M. Kantarjian, MD, discusses the introduction of chimeric antigen receptor T cells and their impact on acute lymphoblastic leukemia.

Nino Balanchivadze, MD, FACP, discusses the rationale for evaluating toxicity based on race in the KEYNOTE-189 study.